TY  - JOUR
A1  - Khudair, Mohammed
A1  - Marcuzzi, Anna
A1  - Ng, Kwok
A1  - Tempest, Gavin Daniel
A1  - Bartoš, František
A1  - Peric, Ratko
A1  - Maier, Maximilian
A1  - Beccia, Flavia
A1  - Boccia, Stefania
A1  - Brandes, Mirko
A1  - Cardon, Greet
A1  - Carlin, Angela
A1  - Castagna, Carolina
A1  - Chaabene, Helmi
A1  - Chalkley, Anna
A1  - Ciaccioni, Simone
A1  - Cieślińska-Świder, Joanna
A1  - Čingienė, Vilma
A1  - Cortis, Cristina
A1  - Corvino, Chiara
A1  - de Geus, Eco J. C.
A1  - Di Baldassarre, Angela
A1  - Di Credico, Andrea
A1  - Drid, Patrik
A1  - Tarazaga, Rosa Ma Fernández
A1  - Gallè, Francesca
A1  - Sánchez, Esther Garcia
A1  - Gebremariam, Mekdes
A1  - Ghinassi, Barbara
A1  - Goudas, Marios
A1  - Hayes, Grainne
A1  - Honorio, Samuel
A1  - Izzicupo, Pascal
A1  - Jahre, Henriette
A1  - Jelsma, Judith
A1  - Juric, Petra
A1  - Kolovelonis, Athanasios
A1  - Kongsvold, Atle
A1  - Kouidi, Evangelia
A1  - Mansergh, Fiona
A1  - Masanovic, Bojan
A1  - Mekonnen, Teferi
A1  - Mork, Paul Jarle
A1  - Murphy, Marie
A1  - O'Hara, Kelly
A1  - Torun, Ayse Ozbil
A1  - Palumbo, Federico
A1  - Popovic, Stevo
A1  - Prieske, Olaf
A1  - Puharic, Zrinka
A1  - Ribeiro, José Carlos
A1  - Rumbold, Penny Louise Sheena
A1  - Sandu, Petru
A1  - Soric, Maroje
A1  - Stavnsbo, Mette
A1  - Syrmpas, Ioannis
A1  - van der Ploeg, Hidde P.
A1  - Van Hoye, Aurélie
A1  - Vilela, Sofia
A1  - Woods, Catherine
A1  - Wunsch, Kathrin
A1  - Caprinica, Laura
A1  - MacDonncha, Ciaran
A1  - Ling, Fiona Chun Man
T1  - DE-PASS Best Evidence Statement (BESt): modifiable determinants of physical activity and sedentary behaviour in children and adolescents aged 5-19 years-a protocol for systematic review and meta-analysis
JF  - BMJ open
N2  - Introduction Physical activity among children and adolescents remains insufficient, despite the substantial efforts made by researchers and policymakers. Identifying and furthering our understanding of potential modifiable determinants of physical activity behaviour (PAB) and sedentary behaviour (SB) is crucial for the development of interventions that promote a shift from SB to PAB. The current protocol details the process through which a series of systematic literature reviews and meta-analyses (MAs) will be conducted to produce a best-evidence statement (BESt) and inform policymakers. The overall aim is to identify modifiable determinants that are associated with changes in PAB and SB in children and adolescents (aged 5-19 years) and to quantify their effect on, or association with, PAB/SB. Methods and analysis A search will be performed in MEDLINE, SportDiscus, Web of Science, PsychINFO and Cochrane Central Register of Controlled Trials. Randomised controlled trials (RCTs) and controlled trials (CTs) that investigate the effect of interventions on PAB/SB and longitudinal studies that investigate the associations between modifiable determinants and PAB/SB at multiple time points will be sought. Risk of bias assessments will be performed using adapted versions of Cochrane's RoB V.2.0 and ROBINS-I tools for RCTs and CTs, respectively, and an adapted version of the National Institute of Health's tool for longitudinal studies. Data will be synthesised narratively and, where possible, MAs will be performed using frequentist and Bayesian statistics. Modifiable determinants will be discussed considering the settings in which they were investigated and the PAB/SB measurement methods used. Ethics and dissemination No ethical approval is needed as no primary data will be collected. The findings will be disseminated in peer-reviewed publications and academic conferences where possible. The BESt will also be shared with policy makers within the DE-PASS consortium in the first instance. Systematic review registration CRD42021282874.
KW  - public health
KW  - health policy
KW  - community child health
Y1  - 2022
U6  - https://doi.org/10.1136/bmjopen-2021-059202
SN  - 2044-6055
VL  - 12
IS  - 9
PB  - BMJ Publishing Group
CY  - London
ER  - 
TY  - JOUR
A1  - Ehmann, Lisa
A1  - Zoller, Michael
A1  - Minichmayr, Iris K.
A1  - Scharf, Christina
A1  - Maier, Barbara
A1  - Schmitt, Maximilian V.
A1  - Hartung, Niklas
A1  - Huisinga, Wilhelm
A1  - Vogeser, Michael
A1  - Frey, Lorenz
A1  - Zander, Johannes
A1  - Kloft, Charlotte
T1  - Role of renal function in risk assessment of target non-attainment after standard dosing of meropenem in critically ill patients
BT  - a prospective observational study
JF  - Critical care
N2  - Background: Severe bacterial infections remain a major challenge in intensive care units because of their high prevalence and mortality. Adequate antibiotic exposure has been associated with clinical success in critically ill patients. The objective of this study was to investigate the target attainment of standard meropenem dosing in a heterogeneous critically ill population, to quantify the impact of the full renal function spectrum on meropenem exposure and target attainment, and ultimately to translate the findings into a tool for practical application. Methods: A prospective observational single-centre study was performed with critically ill patients with severe infections receiving standard dosing of meropenem. Serial blood samples were drawn over 4 study days to determine meropenem serum concentrations. Renal function was assessed by creatinine clearance according to the Cockcroft and Gault equation (CLCRCG). Variability in meropenem serum concentrations was quantified at the middle and end of each monitored dosing interval. The attainment of two pharmacokinetic/pharmacodynamic targets (100% T->MIC, 50% T->4xMIC) was evaluated for minimum inhibitory concentration (MIC) values of 2 mg/L and 8 mg/L and standard meropenem dosing (1000 mg, 30-minute infusion, every 8 h). Furthermore, we assessed the impact of CLCRCG on meropenem concentrations and target attainment and developed a tool for risk assessment of target non-attainment. Results: Large inter-and intra-patient variability in meropenem concentrations was observed in the critically ill population (n = 48). Attainment of the target 100% T->MIC was merely 48.4% and 20.6%, given MIC values of 2 mg/L and 8 mg/L, respectively, and similar for the target 50% T->4xMIC. A hyperbolic relationship between CLCRCG (25-255 ml/minute) and meropenem serum concentrations at the end of the dosing interval (C-8h) was derived. For infections with pathogens of MIC 2 mg/L, mild renal impairment up to augmented renal function was identified as a risk factor for target non-attainment (for MIC 8 mg/L, additionally, moderate renal impairment). Conclusions: The investigated standard meropenem dosing regimen appeared to result in insufficient meropenem exposure in a considerable fraction of critically ill patients. An easy-and free-to-use tool (the MeroRisk Calculator) for assessing the risk of target non-attainment for a given renal function and MIC value was developed.
KW  - beta-Lactam
KW  - Intensive care
KW  - Pharmacokinetics/Pharmacodynamics
KW  - Target attainment
KW  - Renal function
KW  - Risk assessment tool
KW  - Continuous renal replacement therapy
Y1  - 2017
U6  - https://doi.org/10.1186/s13054-017-1829-4
SN  - 1466-609X
SN  - 1364-8535
VL  - 21
PB  - BioMed Central
CY  - London
ER  -